For Sale: Knight Therapeutics Seeks Buyers For Impavido Priority Review Voucher
This article was originally published in The Pink Sheet Daily
Executive Summary
But the small Canadian specialty company says it will be patient in finding the maximum value for the asset, awarded in connection with FDA approval of its leishmaniasis treatment.
You may also be interested in...
Priority Review Weirdness: Tropical Voucher Sells For More; Owner Says It’s Worth Less
Knight Therapeutics says a rare pediatric disease voucher is more valuable than its tropical disease voucher despite the sale price.
Review Cost For Sanofi/Regeneron’s PCSK9 Inhibitor Remains Uncertain
Even after paying BioMarin $67.5 million for the voucher itself, the firms still don’t know how much FDA will charge for a chance to get Praluent to market faster.
PCSK9 Meets PRV: Regeneron’s $70 Mil. Bid To Catch Up To Amgen
Regeneron and its partner Sanofi have become the first biopharma companies to buy a Priority Review Voucher. The $67 million price is a nice bonus for the seller, BioMarin, but probably not the start of a big new market for PRVs.